Carbonic Anhydrase

Cat. No.

A32796

CAS No.

2414598-85-7

hCAIX-IN-12

hCAIX-IN-12 is a selective human carbonic anhydrase IX (hCAIX) inhibitor, demonstrating an IC50 of 0.74 μM for hCAIX and 10.78 μM for carbonic anhydrase II (CAII). This compound exhibits significant antiproliferative effects and promotes apoptosis in cancer cells, along with increasing reactive oxygen species (ROS) production. hCAIX-IN-12 is primarily utilized in research related to colorectal cancer (CRC), providing potential therapeutic insights into tumor growth regulation and oxidative stress responses.

Cat. No.

A32824

CAS No.

2813334-66-4

hCAIX-IN-13

hCAIX-IN-13 is a potent inhibitor of carbonic anhydrase IX (CAIX) with an IC50 value of 6.57 μM. This compound demonstrates significant anti-proliferative effects on cancer cells, inducing apoptosis and thereby offering potential therapeutic insights for cancer research. Its ability to target CAIX makes it a valuable tool for investigating the role of this enzyme in tumor biology and cancer progression.

Cat. No.

A32827

CAS No.

3033040-76-2

hCAIX/XII-IN-1

hCAIX/XII-IN-1 is a selective inhibitor of carbonic anhydrase IX (CAIX) and carbonic anhydrase XII (CAXII), exhibiting inhibition constants (KI) of 0.48 µM and 0.83 µM, respectively. This compound demonstrates significant antiproliferative effects in vitro and effectively induces apoptosis in MCF-7 breast cancer cells. hCAIX/XII-IN-1 is a valuable tool for investigating the role of CAIX and CAXII in cancer biology and therapeutic applications.

Cat. No.

A36429

CAS No.

2091887-74-8

ALP/Carbonic anhydrase-IN-1

ALP/Carbonic Anhydrase-IN-1 is a dual inhibitor of carbonic anhydrase (CA) and alkaline phosphatase (ALP), selectively targeting key isoforms. It demonstrates IC50 values of 0.44 µM for CA-II, 1.61 µM for CA-IX, 0.51 µM for CA-XII, and 0.107 µM for ALP, indicating potent inhibitory activity. This compound is useful in exploring the roles of carbonic anhydrase and alkaline phosphatase in various biological processes and disease models.

Cat. No.

A37090

CAS No.

3032826-63-1

hCA/Wnt/β-catenin-IN-1

hCA/Wnt/β-catenin-IN-1 is a potent inhibitor of human carbonic anhydrases (hCA II, hCA IX, hCA XII) with Ki values of 33.6, 24.1, and 6.8 nM, respectively. This compound effectively reduces P-glycoprotein (P-gp) activity and suppresses the Wnt/β-catenin signaling pathway. It has demonstrated significant inhibition of cancer cell viability, including in the NCI/ADR-RES doxorubicin-resistant cell line, making it a valuable tool for cancer research and the study of multidrug resistance.

Cat. No.

A39352

CAS No.

1424-27-7

Acetazolamide sodium

Acetazolamide sodium is an inhibitor of carbonic anhydrase IX (CA IX) with an IC50 of 30 nM. This compound demonstrates diuretic, antihypertensive, and anti-gonococcal properties, making it valuable in various research applications. Its specific inhibition of CA IX allows for exploration in cancer research, particularly in studies related to tumor microenvironments and metabolic regulation.

Cat. No.

A41163

CAS No.

3393-45-1

5,6-Dihydro-2H-pyran-2-one

5,6-Dihydro-2H-pyran-2-one is a prodrug that functions as a selective inhibitor of carbonic anhydrases. It exhibits inhibitory activity against the tumor-associated isoform hCA IX and the cytoplasmic form hCA I, with Ki values of 1.35 μM and 8.03 μM, respectively. This compound is valuable for investigating mechanisms of hypoxia-related cancer, providing insights into tumor biology and potential therapeutic targets.

Cat. No.

A41165

CAS No.

1330061-67-0

CAIX Inhibitor S4

CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX and XII (CA IX/XII), exhibiting inhibitory constants (Ki) of 7 nM and 2 nM, respectively. It also shows inhibition of carbonic anhydrase II and I, with Ki values of 546 nM and 5600 nM, respectively. This reagent is effective in reducing lung metastasis in an orthotopic MDA-MB-231 mouse model while leaving primary tumor growth unaffected, making it a valuable tool for cancer research and metastasis studies.

Cat. No.

A41166

CAS No.

3368-13-6

Benzolamide

Synonyms: CL11366

Benzolamide is a potent inhibitor of carbonic anhydrase (CA), exhibiting inhibition constants (Ki) of 15 nM for human CA I, 9 nM for human CA II, 94 nM for EcoCAγ, and 78 nM for VchCAγ. Additionally, it inhibits CAS3 with a Ki of 54 nM. This compound is valuable in research focused on glaucoma and seizure disorders, providing insights into the role of carbonic anhydrase in these conditions.

Cat. No.

A41169

CAS No.

3306-62-5

2-Aminobenzenesulfonamide

Synonyms: Orthanilamide

2-Aminobenzenesulfonamide is an inhibitor of carbonic anhydrase IX, an enzyme implicated in various physiological processes, including respiration and acid-base balance. This compound exhibits significant biological activity, making it a valuable tool in cancer research and the study of metabolic disorders. Its ability to modulate carbonic anhydrase activity positions it as a potential lead compound for therapeutic development in conditions where altered enzyme activity plays a crucial role.

Cat. No.

A41173

CAS No.

2736-23-4

Lasamide

Lasamide is a potent inhibitor of human carbonic anhydrases, specifically targeting hCAXII and hCAIX with Ki values of 7.54 nM and 2.76 nM, respectively. This compound exhibits significant biological activity in regulating pH and bicarbonate levels, making it valuable in research areas related to cancer, glaucoma, and metabolic disorders. Its specificity for human carbonic anhydrase isoforms allows for precise investigation of the enzyme's role in physiological and pathological processes.

Cat. No.

A41174

CAS No.

1205-30-7

4-Chloro-3-sulfamoylbenzoic acid

4-Chloro-3-sulfamoylbenzoic acid is a potent inhibitor of human carbonic anhydrase, specifically targeting cytosolic isoforms hCA I and hCA II, as well as transmembrane isoforms hCA IV and hCA IX. Its inhibition of these enzymes is significant in the study of glaucoma-associated conditions and tumor hypoxia-induced responses. This compound is valuable for research applications focused on exploring the roles of carbonic anhydrases in various physiological and pathological processes.

Cat. No.

A41175

CAS No.

301692-76-2

Polmacoxib

Synonyms: CG100649

Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation.

Cat. No.

A41179

CAS No.

694466-00-7

hCAI/II-IN-6

hCAI/II-IN-6 is a selective inhibitor of human carbonic anhydrase isoforms II and VII, exhibiting Ki values of 4.9 nM and 6.5 nM, respectively. This compound demonstrates pronounced anticonvulsant activity and provides protective effects against maximal electroshock (MES) seizures in vivo. hCAI/II-IN-6 serves as a valuable tool for research studies focusing on epilepsy and related neurophysiological conditions.

Cat. No.

A41180

CAS No.

2758231-43-3

Carbonic anhydrase inhibitor 2

Carbonic Anhydrase Inhibitor 2 specifically targets carbonic anhydrase II, functioning as an effective inhibitor. This compound is primarily used in research applications related to the modulation of intraocular pressure and may offer insights into potential therapeutic strategies for glaucoma. Its ability to influence carbonic anhydrase activity highlights its significance in biochemical studies and pharmacological investigations.

Cat. No.

A41181

CAS No.

2925261-76-1

hCAIX-IN-18

hCAIX-IN-18 is a potent inhibitor of carbonic anhydrase (CA), demonstrating inhibition constants (Kis) of 3.5 nM, 9.4 nM, 43.0 nM, and 8.2 nM for human carbonic anhydrases I, II, IX, and XII, respectively. This compound is particularly relevant for cancer research, where it may affect tumor growth and metabolism through the modulation of CA activity. Its specificity and efficacy make it a valuable tool for investigating the role of carbonic anhydrases in various pathological conditions.

Cat. No.

A41184

CAS No.

120279-96-1

Dorzolamide

Synonyms: L671152; MK507

Dorzolamide is a potent inhibitor of carbonic anhydrase II, exhibiting an IC50 of 0.18 nM for red blood cell CA-II and 600 nM for CA-I. This compound is known for its therapeutic applications in reducing intraocular pressure and has demonstrated potential anti-tumor activity. It is a valuable reagent for research in cancer biology and ocular studies.

Cat. No.

A41187

CAS No.

952306-80-8

hCAII-IN-8

hCAII-IN-8 is a selective inhibitor of human carbonic anhydrase II (hCA II), exhibiting an IC50 value of 0.18 μM. This compound is valuable for studying the physiological and pathological roles of hCA II in various biological processes. It may be utilized in drug discovery research related to conditions such as glaucoma, edema, and cancer, where hCA II activity plays a significant role.

Cat. No.

A41190

CAS No.

2748673-86-9

WES-1

WES-1 is a selective inhibitor of carbonic anhydrase IX (CA IX) with a Ki value of 55.9 μM. It demonstrates significant anti-proliferative effects across various cancer cell lines, including leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15), and melanoma (LOX IMVI). This compound serves as a valuable tool in cancer research, particularly in studies focused on tumor metabolism and treatment resistance.

Cat. No.

A41191

CAS No.

3033849-05-4

Carbonic anhydrase inhibitor 17

Carbonic anhydrase inhibitor 17 is a pyridazine-tethered sulfonamide that specifically targets carbonic anhydrase II with an impressive IC50 value of 0.63 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for studying the role of carbonic anhydrases in various physiological and pathological processes. Its application is significant in research areas such as enzyme regulation, metabolic disorders, and cancer biology.

Cat. No.

A41194

CAS No.

132031-90-4

AHR-15010

AHR-15010 is a potent carbonic anhydrase inhibitor with an IC50 value of 0.13 μM. This compound exhibits anti-arthritic activity, making it a valuable tool for research on arthritis and related inflammatory conditions. Its ability to inhibit carbonic anhydrase opens avenues for studying therapeutic strategies in managing arthritis.

Cat. No.

A41195

CAS No.

2497504-81-9

hCAIX-IN-11

hCAIX-IN-11 is a selective inhibitor of carbonic anhydrase IX (hCA IX) and XII (hCA XII), demonstrating Ki values of 32.7 nM and 623.5 nM, respectively. hCA IX and hCA XII are transmembrane isoforms that serve as biomarkers for various tumors, making them critical targets for cancer research. In addition to its role in tumor biology, hCA XII is involved in regulating acid-base homeostasis in both normal and cancerous cells, supporting its relevance in studies of metabolic regulation and tumor microenvironments.

Cat. No.

A41197

CAS No.

2451479-86-8

hCAIX-IN-6

hCAIX-IN-6 is a potent inhibitor of the tumor-associated isoform of carbonic anhydrase IX (hCAIX), displaying significant activity at low nanomolar concentrations. This compound has demonstrated promising selectivity against hCA IX, with potential implications for cancer therapy. hCAIX-IN-6 serves as a valuable lead in the development of innovative therapeutic agents targeting hCAIX-related pathways in cancer treatment.

Cat. No.

A41198

CAS No.

138301-71-0

L-693612

L-693612 is a potent, orally active carbonic anhydrase inhibitor. It effectively modulates bicarbonate and pH levels, making it a valuable tool for research into metabolic and respiratory disorders. This compound supports investigations into the therapeutic potential of carbonic anhydrase inhibition in various biological contexts.

Cat. No.

A41199

CAS No.

2878477-18-8

hCAII-IN-9

hCAII-IN-9 is a potent inhibitor of carbonic anhydrases, specifically exhibiting IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. This compound demonstrates significant potential for research applications related to the modulation of carbonic anhydrase activity in various physiological and pathological conditions. Notably, hCAII-IN-9 does not exhibit permeability across the blood-brain barrier, making it suitable for studies focused on peripheral rather than central effects.